Table of Contents
Sitagliptin is a widely used medication in the management of type 2 diabetes mellitus. Its pharmacology is crucial for healthcare professionals preparing for certification exams, as it highlights the drug’s mechanism of action, pharmacokinetics, and clinical considerations.
Mechanism of Action
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by blocking the enzyme DPP-4, which is responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, sitagliptin increases the levels of active incretins, leading to enhanced insulin secretion and decreased glucagon release in a glucose-dependent manner.
Pharmacokinetics
Sitagliptin is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 4 hours. It has a bioavailability of approximately 87%. The drug is primarily excreted unchanged via the kidneys, with renal clearance being the major route of elimination. Its half-life is approximately 12.4 hours, allowing for once-daily dosing.
Clinical Considerations
Sitagliptin is generally well-tolerated, with a low risk of hypoglycemia when used alone. It is often used in combination with other antidiabetic agents such as metformin. Renal function must be considered when dosing, as dose adjustments are necessary in patients with renal impairment. Common side effects include nasopharyngitis, headache, and gastrointestinal symptoms.
Summary for Certification
- Mechanism: DPP-4 inhibition increases incretin hormones, enhancing insulin secretion.
- Pharmacokinetics: Rapid absorption, renal excretion, once-daily dosing.
- Clinical Use: Monotherapy or combination therapy in type 2 diabetes.
- Important Considerations: Renal dosing adjustments, monitoring for side effects.